8th Oct 2007 07:00
GlaxoSmithKline PLC07 October 2007 Issued: 8th October 2007, London 7am GlaxoSmithKline Appoints Andrew Witty CEO Designate The Board of GlaxoSmithKline plc ("GSK") (LSE & NYSE: GSK) today announced theappointment of Andrew Witty as CEO Designate, GlaxoSmithKline. Andrew Witty, currently President, Pharmaceuticals Europe for GlaxoSmithKline,will succeed Dr Jean-Pierre Garnier following his retirement as Chief ExecutiveOfficer at the end of May 2008. Sir Christopher Gent, Chairman, GlaxoSmithKline said: "Andrew's appointmentfollows a rigorous selection process by the Board of Directors. The fact thatwe have been able to select a successor to JP from three strong internalcandidates is a testament to the quality of management at GSK. The Board isconfident that Andrew will build on JP's considerable achievements which havepositioned GSK as a leader of the pharmaceutical industry." JP Garnier said: "Andrew has made many significant contributions to GSK and I amvery pleased that he is to be our next CEO. I look forward to working with himduring our handover and wish him every success." GlaxoSmithKline - one of the world's leading research-based pharmaceutical andhealthcare companies - is committed to improving the quality of human life byenabling people to do more, feel better and live longer. Simon BicknellCompany Secretary8th October 2007 Enquiries: UK Media enquiries: Philip Thomson (020) 8047 5502 Alice Hunt (020) 8047 5502 Joss Mathieson (020) 8047 5502 Claire Brough (020) 8047 5502 US Media enquiries: Nancy Pekarek (215) 751 7709 Mary Anne Rhyne (919) 483 2839 European Analyst/Investor enquiries: David Mawdsley (020) 8047 5564 Sally Ferguson (020) 8047 5543 US Analyst/ Investor enquiries: Frank Murdolo (215) 751 7002 Tom Curry (215) 751 5419 Notes to Editors: Andrew Witty was appointed President, Pharmaceuticals Europe for GlaxoSmithKlinein January 2003. He is a member of the Corporate Executive Team. Previously, heheld the role of Senior Vice President, Asia Pacific, based in Singapore. Andrew joined Glaxo UK in 1985. He held various positions in the UK, includingDirector of Pharmacy and Distribution, International Product Manager and avariety of other sales & marketing positions. He later served as ManagingDirector, Glaxo South Africa and Area Director for South and East Africa.Immediately prior to his move to Asia Pacific, he was Vice President and GeneralManager, Marketing for Glaxo Wellcome Inc, the company's US subsidiary, where hehad responsibility for strategy development, marketing execution and new productpositioning. While in Singapore Andrew served as Economic Advisor to the Governor ofGuangzhou, China from 2000 to 2002. He was also a member of the SingaporeEconomic Development Board, and sat on the Economic Development Board auditcommittee and the Singapore Land Authority Board. Andrew is a member of the INSEAD UK Council, a member of the interim board ofOSCHR (the Office for Strategic Coordination of Health Research), sits on theImperial College Commercialisation Advisory Board and is a member of the LondonCouncil for the Advancement of Science and Technology. He is a member of thePharma Futures Working Group, and of the UK's newly created Health InnovationCouncil. Andrew is 43 years old and is married with 2 children. He enjoys tennis, runningand watching rugby and cricket. He has a BA in economics from NottinghamUniversity in the UK. This information is provided by RNS The company news service from the London Stock ExchangeRelated Shares:
Glaxosmithkline